Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from December 23, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on March 23, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$50.00 – $53.00Entry zone — fair-value band

$53.10Published — price the day we called it

$61.60Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$36.82Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 24 days.

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Peak gain

+20.8%

peak, from the publication price

Window close

$36.82

end-of-window price, context only

Days to target

Window

December 23, 2025 – March 23, 2026

The thesis — published December 23, 2025

Predicted growth

+16%

over the measurement window

Target price

$61.60

the price the thesis aimed for

Entry zone

$50.00 – $53.00

the fair-value band we waited for

Price at publication

$53.10

published December 23, 2025

Confidence

74%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk jumped after news the FDA approved an oral GLP-1 weight-loss pill. Lots more people are buying than usual, so prices rose quickly. These big news moves often pull back afterward and the company's financial models don't fully match the excitement. Prefer buying on dips near support instead of chasing the spike.

Primary drivers

FDA approval of an oral GLP-1 weight-loss pill
Many traders bought after the news, lifting price
Leading GLP-1 position keeps demand strong
Plan to buy on dips to handle post-news swings

How it played out

NVO: target reached in 24 days

Lyra published NVO on 2025-12-23 at $53.10 with expected growth of 16% and a $61.60 target. The thesis pointed to FDA approval of an oral GLP-1 weight-loss pill, heavy buying after the news, Novo Nordisk's leading GLP-1 position, and a plan to buy dips rather than chase the spike.

Inside the window, NVO reached the target in 24 days. The peak was $64.16 on 2026-01-23, with a peak gain of 20.8%. It later fell and ended at $36.82 on 2026-03-23. The thesis played out on target timing, even though the final price was much lower.

What happened during the window

On January 5, 2026, Novo Nordisk launched the oral Wegovy pill in the U.S., with availability through more than 70,000 pharmacies and mail-order services. On February 24, 2026, Novo Nordisk said it would lower list prices for Wegovy, Ozempic, and Rybelsus to $675 per month starting January 1, 2027.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals